Six1 expands the mouse mammary epithelial stem/progenitor cell pool and induces mammary tumors that undergo epithelial-mesenchymal transition

Journal of Clinical Investigation

Volumn 119, Issue 9, 2009, Pages 2663-2677

  McCoy, Erica L ^a   Iwanaga, Ritsuko ^a   Jedlicka, Paul ^a   Abbey, Nee Shamo ^a   Chodosh, Lewis A ^b   Heichman, Karen A ^c,e   Welm, Alana L ^c   Ford, Heide L ^a,d  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e ARUP LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CYCLIN D1; TRANSCRIPTION FACTOR SIX1; WNT PROTEIN;

ADENOSQUAMOUS CARCINOMA; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BREAST ADENOCARCINOMA; BREAST EPITHELIUM; BREAST TUMOR; CARCINOGENESIS; CELL DIFFERENTIATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HISTOPATHOLOGY; MOUSE; NONHUMAN; PAPILLARY CARCINOMA; POORLY DIFFERENTIATED CARCINOMA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SARCOMATOID CARCINOMA; SECRETORY CARCINOMA; STEM CELL EXPANSION; TISSUE TYPING; TRANSGENIC MOUSE;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; EPITHELIUM; FEMALE; GENE EXPRESSION; HOMEODOMAIN PROTEINS; HUMANS; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MESODERM; MICE; MICE, INBRED NOD; MICE, SCID; MICE, TRANSGENIC; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; TRANSPLANTATION, HETEROLOGOUS;

EID: 70349205537     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI37691     Document Type: Article

References (81)

1. Samuel, S., and Naora, H. 2005. Homeobox gene expression in cancer: insights from developmental regulation and deregulation. Eur. J. Cancer. 41:2428-2437. (Pubitemid 41540620)
2. Pearson, J.C., Lemons, D., and McGinnis, W. 2005. Modulating Hox gene functions during animal body patterning. Nat. Rev. Genet. 6:893-904. (Pubitemid 41782157)
3. Fidler, I.J. 2003. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat. Rev. Cancer. 3:453-458.
4. Brabletz, T., Jung, A., Spaderna, S., Hlubek, F., and Kirchner, T. 2005. Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat. Rev. Cancer. 5:744-749. (Pubitemid 41486367)
5. Guarino, M., Rubino, B., and Ballabio, G. 2007. The role of epithelial-mesenchymal transition in cancer pathology. Pathology. 39:305-318. (Pubitemid 46897605)
6. Thiery, J.P. 2002. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer. 2:442-454.
7. Huber, M.A., Kraut, N., and Beug, H. 2005. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr. Opin. Cell Biol. 17:548-558. (Pubitemid 41267170)
8. Kemler, R., et al. 2004. Stabilization of beta-catenin in the mouse zygote leads to premature epithelial-mesenchymal transition in the epiblast. Development. 131:5817-5824. (Pubitemid 40123899)
9. Mohamed, O.A., Clarke, H.J., and Dufort, D. 2004. Beta-catenin signaling marks the prospective site of primitive streak formation in the mouse embryo. Dev. Dyn. 231:416-424. (Pubitemid 39238068)
10. Yang, L., Lin, C., and Liu, Z.R. 2006. P68 RNA helicase mediates PDGF-induced epithelial mesenchymal transition by displacing Axin from beta-catenin. Cell. 127:139-155. (Pubitemid 44466634)
11. Yook, J.I., et al. 2006. A Wnt-Axin2-GSK3beta cascade regulates Snail1 activity in breast cancer cells. Nat. Cell Biol. 8:1398-1406. (Pubitemid 44835115)
12. Grego-Bessa, J., Diez, J., Timmerman, L., and de la Pompa, J.L. 2004. Notch and epithelial-mesenchyme transition in development and tumor progression: another turn of the screw. Cell Cycle. 3:718-721. (Pubitemid 40187897)
13. Zavadil, J., and Bottinger, E.P. 2005. TGF-beta and epithelial-to- mesenchymal transitions. Oncogene. 24:5764-5774.
14. Mani, S.A., et al. 2008. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 133:704-715. (Pubitemid 351636299)
15. Hamada, S., et al. 2007. Bone morphogenetic protein 4 induces epithelial-mesenchymal transition through MSX2 induction on pancreatic cancer cell line. J. Cell. Physiol. 213:768-774. (Pubitemid 350058270)
16. Peinado, H., Portillo, F., and Cano, A. 2004. Transcriptional regulation of cadherins during development and carcinogenesis. Int. J. Dev. Biol. 48:365-375. (Pubitemid 39360388)
17. Hallaq, H., et al. 2004. A null mutation of Hhex results in abnormal cardiac development, defective vasculogenesis and elevated Vegfa levels. Development. 131:5197-5209. (Pubitemid 39485373)
18. Pan, G., and Thomson, J.A. 2007. Nanog and transcriptional networks in embryonic stem cell pluripotency. Cell Res. 17:42-49. (Pubitemid 46096423)
19. Ford, H.L., Kabingu, E.N., Bump, E.A., Mutter, G.L., and Pardee, A.B. 1998. Abrogation of the G2 cell cycle checkpoint associated with overexpression of HSIX1: a possible mechanism of breast carcinogenesis. Proc. Natl. Acad. Sci. U. S. A. 95:12608-12613.
20. Ozaki, H., et al. 2004. Six1 controls patterning of the mouse otic vesicle. Development. 131:551-562. (Pubitemid 38239998)
21. Li, X., et al. 2003. Eya protein phosphatase activity regulates Six1-Dach-Eya transcriptional effects in mammalian organogenesis. Nature. 426:247-254. (Pubitemid 37463137)
22. Grifone, R., et al. 2005. Six1 and Six4 homeoproteins are required for Pax3 and Mrf expression during myogenesis in the mouse embryo. Development. 132:2235-2249. (Pubitemid 40744482)
23. Ikeda, K., et al. 2007. Six1 is essential for early neurogenesis in the development of olfactory epithelium. Dev. Biol. 311:53-68. (Pubitemid 47588233)
24. Zheng, W., et al. 2003. The role of Six1 in mammalian auditory system development. Development. 130:3989-4000. (Pubitemid 37063418)
25. Coletta, R.D., et al. 2008. Six1 overexpression in mammary cells induces genomic instability and is sufficient for malignant transformation. Cancer Res. 68:2204-2213.
26. Behbakht, K., et al. 2007. Six1 overexpression in ovarian carcinoma causes resistance to TRAIL-mediated apoptosis and is associated with poor survival. Cancer Res. 67:3036-3042. (Pubitemid 46724840)
27. Kobayashi, A., et al. 2008. Six2 defines and regulates a multipotent self-renewing nephron progenitor population throughout mammalian kidney development. Cell Stem Cell 3:169-181.
28. Coletta, R.D., et al. 2004. The Six1 homeoprotein stimulates tumorigenesis by reactivation of cyclin A1. Proc. Natl. Acad. Sci. U. S. A. 101:6478-6483.
29. Reichenberger, K.J., Coletta, R.D., Schulte, A.P., Varella-Garcia, M., and Ford, H.L. 2005. Gene amplification is a mechanism of Six1 overexpression in breast cancer. Cancer Res. 65:2668-2675. (Pubitemid 40490066)
30. Wan, F., et al. 2008. Gene expression changes during HPV-mediated carcinogenesis: a comparison between an in vitro cell model and cervical cancer. Int. J. Cancer. 123:32-40. (Pubitemid 351705189)
31. Ng, K.T., et al. 2006. Clinicopathological significance of homeoprotein Six1 in hepatocellular carcinoma. Br. J. Cancer. 95:1050-1055. (Pubitemid 44606832)
32. Khan, J., et al. 1999. cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene. Proc. Natl. Acad. Sci. U. S. A. 96:13264-13269.
33. Yu, Y., et al. 2004. Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat. Med. 10:175-181. (Pubitemid 38524888)
34. Yu, Y., Davicioni, E., Triche, T.J., and Merlino, G. 2006. The Homeoprotein Six1 transcriptionally activates multiple protumorigenic genes but requires ezrin to promote metastasis. Cancer Res. 66:1982-1989. (Pubitemid 43294906)
35. Li, C.M., et al. 2002. Gene expression in Wilms' tumor mimics the earliest committed stage in the metanephric mesenchymal-epithelial transition. Am. J. Pathol. 160:2181-2190.
36. Gunther, E.J., et al. 2002. A novel doxycycline-inducible system for the transgenic analysis of mammary gland biology. FASEB J. 16:283-292.
37. Wakefield, L.M., et al. 2003. Spontaneous pituitary abnormalities and mammary hyperplasia in FVB/NCr mice: implications for mouse modeling. Comp. Med. 53:424-432.
38. Klaus, A., and Birchmeier, W. 2008. Wnt signalling and its impact on development and cancer. Nat. Rev. Cancer. 8:387-398. (Pubitemid 351589714)
39. Shackleton, M., et al. 2006. Generation of a functional mammary gland from a single stem cell. Nature. 439:84-88. (Pubitemid 43053633)
40. Chen, M.S., et al. 2007. Wnt/beta-catenin mediates radiation resistance of Sca1+ progenitors in an immortalized mammary gland cell line. J. Cell Sci. 120:468-477.
41. Dontu, G., et al. 2003. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 17:1253-1270. (Pubitemid 36583168)
42. Youn, B.S., et al. 2005. Large-scale expansion of mammary epithelial stem cell aggregates in suspension bioreactors. Biotechnol Prog. 21:984-993.
43. Li, Y., et al. 2003. Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. Proc. Natl. Acad. Sci. U. S. A. 100:15853-15858. (Pubitemid 38021079)
44. Rhodes, D.R., et al. 2004. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia. 6:1-6.
45. van de Vijver, M.J., et al. 2002. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347:1999-2009. (Pubitemid 35461656)
46. Ivshina, A.V., et al. 2006. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res. 66:10292-10301.
47. Pawitan, Y., et al. 2005. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res. 7:R953-R964.
48. Micalizzi, D.S., et al. 2009. The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial to mesenchymal transition and metastasis in mice through increasing TGF-β signaling. J. Clin. Invest. 119:2678-2690.
49. White, D.E., Cardiff, R.D., Dedhar, S., and Muller, W.J. 2001. Mammary epithelial-specific expression of the integrin-linked kinase (ILK) results in the induction of mammary gland hyperplasias and tumors in transgenic mice. Oncogene. 20:7064-7072. (Pubitemid 33052198)
50. Schlosser, G., et al. 2008. Eya1 and Six1 promote neurogenesis in the cranial placodes in a SoxB1-dependent fashion. Dev. Biol. 320:199-214.
51. Niwa, H., Miyazaki, J., and Smith, A.G. 2000. Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat. Genet. 24:372-376. (Pubitemid 30187435)
52. Chambers, I., et al. 2003. Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell. 113:643-655. (Pubitemid 36694189)
53. Mitsui, K., et al. 2003. The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell. 113:631-642. (Pubitemid 36694188)
54. Gidekel, S., Pizov, G., Bergman, Y., and Pikarsky, E. 2003. Oct-3/4 is a dose-dependent oncogenic fate determinant. Cancer Cell. 4:361-370. (Pubitemid 37491097)
55. Zou, D., et al. 2008. Eya1 gene dosage critically affects the development of sensory epithelia in the mammalian inner ear. Hum. Mol. Genet. 17:3340-3356.
56. Self, M., et al. 2006. Six2 is required for suppression of nephrogenesis and progenitor renewal in the developing kidney. EMBO J. 25:5214-5228. (Pubitemid 44658538)
57. Miyoshi, K., et al. 2002. Activation of different Wnt/beta-catenin signaling components in mammary epithelium induces transdifferentiation and the formation of pilar tumors. Oncogene. 21:5548-5556. (Pubitemid 34983544)
58. Varmus, H. 1988. Regulation of HIV and HTLV gene expression. Genes Dev. 2:1055-1062.
59. Lane, T.F., and Leder, P. 1997. Wnt-10b directs hypermorphic development and transformation in mammary glands of male and female mice. Oncogene. 15:2133-2144. (Pubitemid 27493902)
60. Imbert, A., Eelkema, R., Jordan, S., Feiner, H., and Cowin, P. 2001. Delta N89 beta-catenin induces precocious development, differentiation, and neoplasia in mammary gland. J. Cell Biol. 153:555-568. (Pubitemid 34280142)
61. Spoelstra, N.S., et al. 2006. The transcription factor ZEB1 is aberrantly expressed in aggressive uterine cancers. Cancer Res. 66:3893-3902.
62. Welm, A.L., Kim, S., Welm, B.E., and Bishop, J.M. 2005. MET and MYC cooperate in mammary tumorigenesis. Proc. Natl. Acad. Sci. U. S. A. 102:4324-4329. (Pubitemid 40397110)
63. Moraes, R.C., et al. 2007. Constitutive activation of smoothened (SMO) in mammary glands of transgenic mice leads to increased proliferation, altered differentiation and ductal dysplasia. Development. 134:1231-1242.
64. Stingl, J., et al. 2006. Purification and unique properties of mammary epithelial stem cells. Nature. 439:993-997. (Pubitemid 43292419)
65. Sanchez-Carbayo, M., Socci, N.D., Lozano, J., Saint, F., and Cordon-Cardo, C. 2006. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J. Clin. Oncol. 24:778-789. (Pubitemid 46622045)
66. Sun, L., et al. 2006. Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell. 9:287-300.
67. French, P.J., et al. 2005. Gene expression profiles associated with treatment response in oligodendrogliomas. Cancer Res. 65:11335-11344. (Pubitemid 41821690)
68. Graudens, E., et al. 2006. Deciphering cellular states of innate tumor drug responses. Genome Biol. 7:R19. (Pubitemid 43871874)
69. Chung, C.H., et al. 2004. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell. 5:489-500. (Pubitemid 38610250)
70. Stearman, R.S., et al. 2005. Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model. Am. J. Pathol. 167:1763-1775.
71. Beer, D.G., et al. 2002. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat. Med. 8:816-824.
72. Bhattacharjee, A., et al. 2001. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc. Natl. Acad. Sci. U. S. A. 98:13790-13795. (Pubitemid 33115977)
73. Powell, C.A., et al. 2003. Gene expression in lung adenocarcinomas of smokers and nonsmokers. Am. J. Respir. Cell. Mol. Biol. 29:157-162. (Pubitemid 36936642)
74. Wachi, S., Yoneda, K., and Wu, R. 2005. Interactome-transcriptome analysis reveals the high centrality of genes differentially expressed in lung cancer tissues. Bioinformatics. 21:4205-4208. (Pubitemid 41724298)
75. Adib, T.R., et al. 2004. Predicting biomarkers for ovarian cancer using gene-expression microarrays. Br. J. Cancer. 90:686-692.
76. Ishikawa, M., et al. 2005. Experimental trial for diagnosis of pancreatic ductal carcinoma based on gene expression profiles of pancreatic ductal cells. Cancer Sci. 96:387-393. (Pubitemid 41179739)
77. Vanaja, D.K., Cheville, J.C., Iturria, S.J., and Young, C.Y. 2003. Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res. 63:3877-3882.
78. Yu, Y.P., et al. 2004. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J. Clin. Oncol. 22:2790-2799.
79. Cutcliffe, C., et al. 2005. Clear cell sarcoma of the kidney: up-regulation of neural markers with activation of the sonic hedgehog and Akt pathways. Clin. Cancer Res. 11:7986-7994. (Pubitemid 41698739)
80. Boer, J.M., et al. 2001. Identification and classification of differentially expressed genes in renal cell carcinoma by expression profiling on a global human 31,500-element cDNA array. Genome Res. 11:1861-1870. (Pubitemid 33100427)
81. Lenburg, M.E., et al. 2003. Previously unidentified changes in renal cell carcinoma gene expression identified by parametric analysis of microarray data. BMC Cancer. 3:31.